Last reviewed · How we verify
Intra-Lesional MMR Immunotherapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Intra-Lesional MMR Immunotherapy (Intra-Lesional MMR Immunotherapy) — Abeer Mohamed Abdelaziz Elkholy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intra-Lesional MMR Immunotherapy TARGET | Intra-Lesional MMR Immunotherapy | Abeer Mohamed Abdelaziz Elkholy | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intra-Lesional MMR Immunotherapy CI watch — RSS
- Intra-Lesional MMR Immunotherapy CI watch — Atom
- Intra-Lesional MMR Immunotherapy CI watch — JSON
- Intra-Lesional MMR Immunotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Intra-Lesional MMR Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-lesional-mmr-immunotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab